Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue EBioMedicine Année : 2023

Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells

Emilie Lebarbier
Michael Zimmermann
  • Fonction : Auteur
  • PersonId : 1096561
Gwen Lomberk
Raul Urrutia
  • Fonction : Auteur
  • PersonId : 938373

Résumé

BACKGROUND: Systems biology leveraging multi-OMICs technologies, is rapidly advancing development of precision therapies and matching patients to targeted therapies, leading to improved responses. A new pillar of precision oncology lies in the power of chemogenomics to discover drugs that sensitizes malignant cells to other therapies. Here, we test a chemogenomic approach using epigenomic inhibitors (epidrugs) to reset patterns of gene expression driving the malignant behavior of pancreatic tumors. METHODS: We tested a targeted library of ten epidrugs targeting regulators of enhancers and super-enhancers on reprogramming gene expression networks in seventeen patient-derived primary pancreatic cancer cell cultures (PDPCCs), of both basal and classical subtypes. We subsequently evaluated the ability of these epidrugs to sensitize pancreatic cancer cells to five chemotherapeutic drugs that are clinically used for this malignancy. FINDINGS: To comprehend the impact of epidrug priming at the molecular level, we evaluated the effect of each epidrugs at the transcriptomic level of PDPCCs. The activating epidrugs showed a higher number of upregulated genes than the repressive epidrugs (χ(2) test p-value <0.01). Furthermore, we developed a classifier using the baseline transcriptome of epidrug-primed-chemosensitized PDPCCs to predict the best epidrug-priming regime to a given chemotherapy. Six signatures with a significant association with the chemosensitization centroid (R ≤ -0.80; p-value < 0.01) were identified and validated in a subset of PDPCCs. INTERPRETATION: We conclude that targeting enhancer-initiated pathways in patient-derived primary cells, represents a promising approach for developing new therapies for human pancreatic cancer.
Fichier principal
Vignette du fichier
2023_priming_ebiomedicine.pdf (1.89 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04100206 , version 1 (21-11-2023)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Nicolas A Fraunhoffer, Aura I Moreno Vega, Analía Meilerman Abuelafia, Marie Morvan, Emilie Lebarbier, et al.. Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. EBioMedicine, 2023, 92, pp.104602. ⟨10.1016/j.ebiom.2023.104602⟩. ⟨hal-04100206⟩
97 Consultations
31 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More